Alan R. Boobis spends much of his time researching Biochemistry, Internal medicine, Endocrinology, Microsome and Carcinogen. Urine and Enzyme are among the areas of Biochemistry where Alan R. Boobis concentrates his study. His studies in Cytochrome P450 and CYP1A2 are all subfields of Internal medicine research.
His Cytochrome P450 research integrates issues from Molecular biology, Gene expression and Hepatic stellate cell. He combines subjects such as Cytochrome, Phenacetin, Methylcholanthrene and Pyrene with his study of Microsome. His work carried out in the field of Carcinogen brings together such families of science as Polycyclic Hydrocarbons, Inhalation, Inhalation exposure and Potency.
His primary scientific interests are in Biochemistry, Microsome, Internal medicine, Endocrinology and Carcinogen. His study in Biochemistry concentrates on Cytochrome, Cytochrome P450, Enzyme, In vitro and Metabolism. His work carried out in the field of Cytochrome P450 brings together such families of science as Molecular biology, Gene expression and Isozyme.
His Microsome research is multidisciplinary, incorporating perspectives in Human liver, Chromatography, Phenacetin and Benzopyrene. His studies deal with areas such as Methylcholanthrene and Potency as well as Internal medicine. He has included themes like Mechanism of action and Partial agonist in his Endocrinology study.
The scientist’s investigation covers issues in Risk analysis, Environmental health, Endocrine system, Endogeny and Hormone. His Exposure assessment study in the realm of Environmental health connects with subjects such as Veterinary Drugs. His work focuses on many connections between Exposure assessment and other disciplines, such as Food processing, that overlap with his field of interest in Biotechnology.
Research on Internal medicine and Endocrinology is a part of his Endogeny study. The concepts of his Hormone study are interwoven with issues in Ingestion and Partial agonist. His biological study deals with issues like Biochemical engineering, which deal with fields such as Carcinogen and Mode of action.
Alan R. Boobis mainly investigates Risk analysis, Mode of action, Carcinogen, Toxicology and Carcinogenesis. The study incorporates disciplines such as Biotechnology and Food safety in addition to Risk analysis. In his research on the topic of Mode of action, NAPQI, Metabolite, Glutathione, Drug metabolism and Acetaminophen is strongly related with Bioinformatics.
Alan R. Boobis regularly links together related areas like Genotoxicity in his Carcinogen studies. His Genotoxicity research includes elements of Epigenetics, DNA repair and Biochemical engineering. His Carcinogenesis study combines topics in areas such as Cell, Bioassay, In silico and Computational biology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Methods of in vitro toxicology.
G Eisenbrand;B Pool-Zobel;V Baker;M Balls.
Food and Chemical Toxicology (2002)
Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells.
C. Rodríguez-Antona;M. T. Donato;A. Boobis;R. J. Edwards.
Managing the challenge of chemically reactive metabolites in drug development
B. Kevin Park;Alan Boobis;Stephen Clarke;Chris E P Goldring.
Nature Reviews Drug Discovery (2011)
IPCS framework for analyzing the relevance of a cancer mode of action for humans.
Alan R. Boobis;John E. Doe;Barbara Heinrich-Hirsch;M. E. (Bette) Meek.
Critical Reviews in Toxicology (2006)
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.
Zoe E Barter;Martin K Bayliss;Philip H Beaune;Alan R Boobis.
Current Drug Metabolism (2007)
Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework.
M E Bette Meek;Alan R Boobis;Kevin M Crofton;Gerhard Heinemeyer.
Regulatory Toxicology and Pharmacology (2011)
Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.
Anna Westlind-Johnsson;Sarah Malmebo;Anna Johansson;Charlotta Otter.
Drug Metabolism and Disposition (2003)
Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.
Christoph Sachse;Upinder Bhambra;Gillian Smith;Tracy J. Lightfoot.
British Journal of Clinical Pharmacology (2003)
Scientific Opinion on the public health hazards to be covered by inspection of meat (swine)
Olivier Andreoletti;Herbert Budka;Sava Buncic;John D Collins.
EFSA Journal (2011)
Risk characterisation of chemicals in food and diet.
A. G. Renwick;S. M. Barlow;Irva Hertz-Picciotto;A. R. Boobis.
Food and Chemical Toxicology (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: